TIP_link_300x300.jpg
Non-Alcoholic Steatohepatitis (NASH) Market Worth $24.26Bn, Globally, by 2028 at 47.1% CAGR - Exclusive Report by The Insight Partners
May 04, 2022 08:37 ET | The Insight Partners
New York, May 04, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis...
Vantage Market Research.png
NASH (Non-Alcoholic Steatohepatitis) Market to Reach USD 21,879 Million by 2028 - Powered by Increasing Pharmaceutical R&D Expenditure and Escalating Obese Population- Vantage Market Research
February 09, 2022 05:06 ET | Vantage Market Research
WASHINGTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Non-Alcoholic Steatohepatitis (NASH) Market finds that growing demand for ideal NASH...
22157.jpg
Global NASH Market Report 2021: Market was Valued at $3,369.12 Million in 2020 - Forecast to 2026
April 13, 2021 07:13 ET | Research and Markets
Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Global NASH Market - Analysis By Drug Type, Sales Chanel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and...
22157.jpg
Global Non-alcoholic Steatohepatitis (NASH) Market 2021-2038: Increased Competition from New Product Launches will Shape the NASH Market
March 23, 2021 08:08 ET | Research and Markets
Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Non-alcoholic steatohepatitis (NASH) Market and Forecast Analysis to 2038" report has been added to ResearchAndMarkets.com's offering. There are...
LOGO.jpg
ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT
January 01, 2021 19:15 ET | The Rosen Law Firm PA
NEW YORK, Jan. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...
LOGO.jpg
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ICPT
December 03, 2020 19:45 ET | The Rosen Law Firm PA
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...
22157.jpg
Global Primary Sclerosing Cholangitis Market 2017-2020 & 2030 Featuring Gilead Sciences, HighTide Biopharma, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr Falk Pharma
October 14, 2020 04:04 ET | Research and Markets
Dublin, Oct. 14, 2020 (GLOBE NEWSWIRE) -- The "Primary Sclerosing Cholangitis - Market Insights, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. ...